Middle East and Africa Lung Transplant Therapeutics Market, By Product (Immunosuppressant Drugs, Organ Preservation Products, Tissue Products, and Others), Indication (Chronic Obstructive Pulmonary Diseases (COPD), Pulmonary Fibrosis, Septic Lung Disease, Pulmonary Hypertension, Cystic Fibrosis, Interstitial Pulmonary Fibrosis, Emphysema, Sarcoidosis, Primary Pulmonary Arterial Hypertension, and Others), Type (Cadaveric Lung Transplantation, Living Lung Transplantation), Technique (Single-Lung Transplantation, Bilateral-Lung Transplantation, Heart-Lung Transplantation, and Double Lung Transplantation), Patient Demographics (Geriatric, Adult, Paediatric), End Users (Hospital, Transplant Centres, Specialty Centres, and Others), Country (Saudi Arabia, South Africa, Israel, U.A.E., Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights : Middle East and Africa Lung Transplant Therapeutics Market
Middle-East and Africa lung transplant therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 2.5% in the forecast period of 2022 to 2029 and is expected to reach USD 2.78 million by 2029. Increase in new innovative treatment for surgeries and therapies and rise in respiratory chronic diseases due to rise in pollution are the major drivers that may propel the demand of the market in the forecast period.
A lung transplant is a surgical procedure done to remove an unhealthy lung and replace it with a healthy lung from another person. Unhealthy or damaged lungs can make it difficult for a patient body to get the oxygen it needs to survive the day to day need of body functions like respiration which help in balancing pH in the body by increasing the ventilation rate whenever the acidity rise due to carbon dioxide accumulation to expel more of unwanted gas which helps in balancing pH. A variety of diseases like asthma, inflammation in bronchial tubes and lungs, and the buildup of fluid in lungs, and lung cancer and conditions can damage the lungs and hamper their ability to function effectively.
Increasing drug approvals, rise in clinical trials, high incidence of chronic disease, and ongoing research to increase the therapeutics application is expected to drive the market's growth. However, fewer donors for organ donation and the high cost of lung transplant procedures may hamper the market growth. Meanwhile, rising healthcare spending, strategic initiatives by market players, technological advancements in lung transplantation may create opportunities for market growth. Stringent regulatory framework and complications associated with lung transplantation may challenge the market growth.
The Middle East and Africa lung transplant therapeutics market report provide details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief; our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Lung Transplant Therapeutics Market Scope and Market Size
The Middle East and Africa lung transplant therapeutics market is segmented into product, type, indication, technique, patient demographics, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Middle East and Africa lung transplant therapeutics market is segmented into immunosuppressant drugs, tissue products, organ preservation products, and others. In 2022, the immunosuppressant drugs segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the increase in the effectiveness of immune system suppressant drugs in patients to avoid lung rejection.
- On the basis of type, the Middle East and Africa lung transplant therapeutics market is segmented into cadaveric lung transplantation and living lung transplantation. In 2022, the cadaveric lung transplantation segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to increased organ donation and its applications.
- On the basis of indication, the Middle East and Africa lung transplant therapeutics market is segmented into chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, septic lung disease, pulmonary hypertension, cystic fibrosis, interstitial pulmonary fibrosis, emphysema, primary pulmonary arterial hypertension sarcoidosis, and others. In 2022, the cystic fibrosis segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the increase in the vulnerable older patient population of cystic fibrosis patients in region.
- On the basis of technique, the Middle East and Africa lung transplant therapeutics market is segmented into single-lung transplantation, bilateral-lung transplantation, heart-lung transplantation, and double lung transplantation. In 2022, the single-lung transplantation (SLT) segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the surge in advanced lung transplantation procedures.
- On the basis of patient demographics, the Middle East and Africa lung transplant therapeutics market is segmented into adult, pediatric, and geriatric. In 2022, the adult segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to the increase in adult population.
- On the basis of end users, the Middle East and Africa lung transplant therapeutics market is segmented into hospital, transplant centers, specialty centers, and others. In 2022, the hospital segment is expected to dominate the Middle East and Africa lung transplant therapeutics market due to hospitals as the primary point of healthcare and effective place for the surgeries with skilled doctors and increased awareness regarding organ donation, registration, and chronic diseases.
Middle East and Africa Lung Transplant Therapeutics Market Country Level Analysis
The Middle East and Africa lung transplant therapeutics market is analyzed, and market size information is provided based on product, type, indication, technique, patient demographics, and end users.
Some of the countries covered in the Middle East and Africa lung transplant therapeutics market are Saudi Arabia, South Africa, U.A.E., Israel, Egypt and Rest of Middle East and Africa.
The immunosuppressant drugs segment in the Middle East and African region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing clinical trials and research development for the prevention of chronic diseases. Saudi Arabia is expected to lead the growth of the Middle East and Africa market due to increasing lung transplant surgeries every year results in larger approval of drugs for transplant. South Africa is expected to dominate with a continuous increase in investments for research and development.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and African brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Healthcare Expenditure and Chronic Diseases boost the Middle East and Africa Lung Transplant Therapeutics Market Growth
The Middle East and Africa lung transplant therapeutics market also provide you with detailed market analysis for every country's growth in the lung transplant industry with sales, impact of advancement in the lung transplant technology, and changes in regulatory scenarios with their support for the lung transplant therapeutics market. The data is available for historic period 2011 to 2020.
Competitive Landscape and Middle East and Africa Lung Transplant Therapeutics Market Share Analysis
The Middle East and Africa lung transplant therapeutics market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company's focus on the Middle East and Africa lung transplant therapeutics market.
Some major manufacturers for the Middle East and Africa lung transplant therapeutics market are Bridge to Life Ltd, Viatris Inc., BioLife Solutions, Pfizer Inc., F.Hoffmann-La Roche Ltd., Panacea Biotec Ltd., Accord-UK Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., among others.
Various market players provides better healthcare services which are also accelerating the Middle East and Africa lung transplant therapeutics market
For instance,
- In January 2022, Hikma Pharmaceuticals PLC expanded in Canada with Teligent sterile injectable, including a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products, and a pipeline of seven additional products, four of which are approved by Health Canada. This portfolio of exciting products will enable the company to expand North American business and develop a solid position in this important market
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other market players enhance the company in the Middle East and Africa lung transplant therapeutics market, which also benefits the organization to improve its offering.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
5 INSURANCE AND REIMBURSEMENT - MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET
5.1 U.S.
5.2 EUROPE
5.3 CANADA
5.4 INDIA
6 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS
6.1 REGULATION IN THE U.S.
6.2 REGULATION IN EUROPE
6.3 REGULATION IN NEW ZEALAND
6.4 REGULATION IN AUSTRALIA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 INCREASING DRUG APPROVALS
7.2 RESTRAINTS
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE SPENDING
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 IMMUNOSUPPRESSANT DRUGS
9.2.1 BY CLASS
9.2.1.1 CALCINEURIN INHIBITORS
9.2.1.1.1 TACROLIMUS
9.2.1.1.2 CYCLOSPORIN
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS
9.2.1.2.1 MYCOPHENOLATE MOFETIL
9.2.1.2.2 MYCOPHENOLATE SODIUM
9.2.1.2.3 AZATHIOPRINE
9.2.1.3 M-TOR INHIBITOR
9.2.1.3.1 SIROLIMUS
9.2.1.3.2 EVEROLIMUS
9.2.1.4 STEROIDS
9.2.1.4.1 METHYLPREDNISOLONE
9.2.1.4.2 PREDNISONE
9.2.1.5 MONOCLONAL ANTIBODY
9.2.1.5.1 BASILIXIMAB
9.2.1.5.2 MUROMONAB
9.2.1.6 OTHERS
9.2.2 BY DRUG TYPE
9.2.2.1 BRANDED
9.2.2.2 GENERIC
9.2.3 ROUTE OF ADMINISTRATION
9.2.3.1 ORAL ADMINISTRATION
9.2.3.2 PARENTERAL ADMINISTRATION
9.3 ORGAN PRESERVATION PRODUCTS
9.3.1 PERFADEX
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION
9.3.3 LIFOR
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION
9.3.5 RENOGRAF
9.3.6 OTHERS
9.4 TISSUE PRODUCT
9.5 OTHERS
10 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE
10.1 OVERVIEW
10.2 SINGLE-LUNG TRANSPLANT (SLT)
10.3 DOUBLE LUNG TRANSPLANT
10.4 BILATERAL LUNG TRANSPLANT (BLT)
10.5 HEART-LUNG TRANSPLANT
11 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CADAVERIC LUNG TRANSPLANT
12.3 LIVING LUNG TRANSPLANT
13 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 CYSTIC FIBROSIS
13.3 PULMONARY FIBROSIS
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
13.5 INTERSTITIAL PULMONARY FIBROSIS
13.6 PULMONARY HYPERTENSION
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION
13.8 EMPHYSEMA
13.9 SARCOIDOSIS
13.1 SEPTIC LUNG DISEASE
13.11 OTHERS
14 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 TRANSPLANT CENTERS
14.4 SPECIALTY CENTERS
14.5 OTHERS
15 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION
15.1 MIDDLE EAST AND AFRICA
15.1.1 SAUDI ARABIA
15.1.2 SOUTH AFRICA
15.1.3 ISRAEL
15.1.4 UAE
15.1.5 REST OF MIDDLE EAST AND AFRICA
16 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ASTELLAS PHARMA INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 DR. REDDY’S LABORATORIES LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 F.HOFFMANN-LA ROCHE LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 HIKMA PHARMACEUTICALS PLC
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 APOTEX INC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 XVIVO
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ACCORD-UK LTD
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BIOLIFE SOLUTIONS
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BRIDGE TO LIFE LTD
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 DETRAXI, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 DR.FRANZ KOHLER CHEMIE GBMH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 INTAS PHARMACEUTICALS LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 OSE-IMMUNO
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 PANACEA BIOTEC LTD.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 PARAGONIX TECHNOLOGIES, INC
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENTS
18.17.3.1 PRODUCT LAUNCH
18.17.3.2 PARTNERSHIP
18.18 PFIZER INC.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 VIATRIS, INC
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.20ST CENTURY MEDICINE
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA TISSUE PRODUCT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA SINGLE-LUNG TRANSPLANT (SLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA DOUBLE LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA BILATERAL LUNG TRANSPLANT (BLT) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA HEART-LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ADULTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA GERIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PEDIATRIC IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA CADAVERIC LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA LIVING LUNG TRANSPLANT IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA CYSTIC FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA INTERSTITIAL PULMONARY FIBROSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA PULMONARY HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA PRIMARY PULMONARY ARTERIAL HYPERTENSION IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA EMPHYSEMA IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA SARCOIDOSIS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA SEPTIC LUNG DISEASE IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA HOSPITAL IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA TRANSPLANT CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA SPECIALTY CENTERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 64 SAUDI ARABIA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 65 SAUDI ARABIA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 66 SAUDI ARABIA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 67 SAUDI ARABIA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 68 SAUDI ARABIA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 SOUTH AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 76 SOUTH AFRICA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 77 SOUTH AFRICA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 78 SOUTH AFRICA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 79 SOUTH AFRICA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 80 SOUTH AFRICA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 81 SOUTH AFRICA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 82 SOUTH AFRICA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 SOUTH AFRICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 SOUTH AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 85 SOUTH AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 SOUTH AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 87 SOUTH AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 88 SOUTH AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 89 ISRAEL LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 90 ISRAEL IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 91 ISRAEL CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 92 ISRAEL ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 93 ISRAEL M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 94 ISRAEL STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 95 ISRAEL MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 96 ISRAEL IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 97 ISRAEL IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 98 ISRAEL ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 99 ISRAEL LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 100 ISRAEL LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 ISRAEL LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 102 ISRAEL LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 103 ISRAEL LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 UAE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 105 UAE IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 106 UAE CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 107 UAE ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 108 UAE M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 109 UAE STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 110 UAE MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 111 UAE IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 112 UAE IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 UAE ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 114 UAE LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 115 UAE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 UAE LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 117 UAE LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 118 UAE LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 119 REST OF MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR LUNG TRANSPLANT THERAPEUTICS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET
FIGURE 16 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021
FIGURE 17 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021
FIGURE 21 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021
FIGURE 25 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021
FIGURE 29 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021
FIGURE 33 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)
FIGURE 35 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021
FIGURE 37 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 39 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)
FIGURE 41 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)
FIGURE 42 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 43 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 44 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)
FIGURE 45 MIDDLE EAST AND AFRICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
